Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33) (GLP-2ant)

University of Copenhagen

Status: Completed

Conditions: Healthy

Treatments: Other: Agonist injection; Other: Saline injection; Other: 1nmol antagonist infusion; Other: 4 nmol antagonist infusion; Other: Saline infusion

Study type: Interventional

Funder types: Other

Identifiers

NCT06774807

H-24000668

Details and patient eligibility

About

This project will describe the role of physiological levels of GLP-2 in regulating the blood flow to the intestines and the effect of the antagonist GLP-2(3-33) in blocking these effects of GLP-2.

Full description

Ten healthy participants will meet fasting and attend four randomized experimental days of MRI-scans of the abdomen. Each day will include subcutaneous injections of GLP-2 or saline and intravenous infusion of either the GLP-2 (3-33) antagonist or saline. The infusion start at timepoint -20, while the subcutaneous injection is given to timepoint 0 and the participant will lay in the scanner in one hour after injection. Eight MR-scans are done repeatedly to measure the blood flow in larger abdominal vessels and four blood samples are taken during the experimental day for analysis of GLP-2(1-33), GLP-2(3-33) and bone markers.

Enrollment: 10 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 18-70 years
• BMI 19-28 kg/m2

Exclusion criteria

• Chronic illness that affects the cardiovascular system or gastrointestinal tract
• Treatment with medicine or supplements that cannot be paused for 12 hours
• Intake of above 14 alcoholic drinks per week or substance abuse
• Liver enzymes (ALAT) above 2 times normal values
• Decreased kidney function (eGFR below 90 or creatinine levels over reference value)
• Low blood percentage (hemoglobin below reference value)
• Any condition or disease that the persons responsible for the study find would interfere with the participation of the study.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

10 participants in 4 patient groups, including a placebo group

Saline injection + Saline infusion (SAL-SAL)

Placebo Comparator group

Description:

Saline subcutaneous injection, Intravenous saline infusion (NaCl (9 mg/ml))

Treatment:

Other: Saline infusion

Other: Saline injection

GLP-2 agonist injection + Saline infusion (AGO-SAL)

Active Comparator group

Description:

Subcutaneous injection of GLP-2 (1-33) agonist, Intravenous infusion of saline (NaCl (9 mg/ml))

Treatment:

Other: Saline infusion

Other: Agonist injection

GLP-2 agonist injection + GLP-2 1 nmol antagonist infusion (AGO-1ANT)

Experimental group

Description:

Subcutaneous Injection of GLP-2 (1-33) agonist, Intravenous infusion of 1 nmol/kg/min GLP-2 (3-33) antagonist

Treatment:

Other: 1nmol antagonist infusion

Other: Agonist injection

GLP-2 agonist injection + GLP-2 4 nmol antagonist infusion (AGO-4ANT)

Experimental group

Description:

Subcutaneous Injection of GLP-2 (1-33) agonist, Intravenous infusion of 4 nmol/kg/min GLP-2 (3-33) antagonist

Treatment:

Other: 4 nmol antagonist infusion

Other: Agonist injection